Biosearch Technologies Expands Licensing of QIAGEN Scorpions® Patents


Updated : Mon, September 19, 2022 @ 2:12 PM

Originally published : Thu, Aug 12, 2010 @ 10:41 AM

Scorpions PrimersBiosearch Technologies today announces that it has entered into a new license relationship with QIAGEN (NASDAQ: QIA, Frankfurt Prime Standard) providing broad commercialisation rights to Scorpions Primers.  This agreement allows Biosearch the right to manufacture, catalog, and sell Scorpions primer assays into the research, applied, and infectious disease testing markets.

To read the entire story, read the full press release" target="_self">read the full press release.

Leave a comment

Subscribe to our blog

About LGC, Biosearch Technologies

LGC, Biosearch Technologies is the complete Genomics portfolio from LGC. Providing genomic analysis tools, instrumentation and services to the genomic scientific discovery sector worldwide, with focus on across ag bio, pharma and molecular diagnostics. Visit our home page to view our products and services.

Posts by popularity

Follow @BiosearchTech on Twitter

Become a Fan on Facebook!